Does Rallies show Form 4 insider transactions for HOTH?

Yes. Rallies tracks HOTH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is HOTH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HOTH. It does not provide personalized investment advice.

HOTH (Hoth Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Hoth Therapeutics, Inc. Common Stock (HOTH) is a publicly traded Healthcare sector company. As of May 21, 2026, HOTH trades at $0.60 with a market cap of $11.72M and a P/E ratio of -0.66. HOTH moved +0.10% today. Year to date, HOTH is -43.41%; over the trailing twelve months it is -29.07%. Its 52-week range spans $0.49 to $3.80. Rallies surfaces HOTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading HOTH stock inside the company?

Recent HOTH insider activity includes Knie Robb bought 25.00K, Knie Robb bought 10.00K, Knie Robb bought 10.00K, AIkido Pharma Inc. sold 400.00K, and Hayes Anthony sold 400.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

HOTH Key Metrics

Key financial metrics for HOTH
Metric	Value
Price	$0.60
Market Cap	$11.72M
P/E Ratio	-0.66
EPS	$-0.90
Dividend Yield	0.00%
52-Week High	$3.80
52-Week Low	$0.49
Volume	899
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-12.47M
Gross Margin	0.00%

Recent HOTH Insider Trades

Knie Robb bought 25.00K (~$16.75K) on Aug 16, 2024.
Knie Robb bought 10.00K (~$3.90K) on Sep 19, 2022.
Knie Robb bought 10.00K (~$4.00K) on Sep 16, 2022.
AIkido Pharma Inc. sold 400.00K (~$500.00K) on May 26, 2020.
Hayes Anthony sold 400.00K (~$500.00K) on May 26, 2020.

Latest HOTH News

Hoth Therapeutics Secures Spain Approval for HT-001 Phase 2a, Reports 65% Symptom Relief — May 5, 2026
Hoth Therapeutics’ GDNF Cuts Srebf1 and Boosts Pparα, Outpacing Semaglutide — Apr 13, 2026
Hoth Therapeutics Closes $2.0M Direct Offering of 2.86M Shares with Warrants — Apr 2, 2026
Hoth Therapeutics' HT-001 Hits ARIGA ≤1 by Week Six with 65% Symptom Relief and Hungary Trial Expansion — Apr 1, 2026
Hoth Therapeutics Rolls Out OpenClaw AI Platform to Accelerate Discovery Across Three Indications — Mar 26, 2026

HOTH Analyst Consensus

HOTH analyst coverage data. Average price target: $0.00.

Common questions about HOTH

Who is trading HOTH stock inside the company?: Recent HOTH insider activity includes Knie Robb bought 25.00K, Knie Robb bought 10.00K, Knie Robb bought 10.00K, AIkido Pharma Inc. sold 400.00K, and Hayes Anthony sold 400.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HOTH?: Yes. Rallies tracks HOTH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HOTH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HOTH. It does not provide personalized investment advice.